Corcept Therapeutics Incorporated Stock Today
| CORT Stock | USD 57.11 1.21 2.07% |
PerformanceInsignificant
| Odds Of DistressVery Low
|
Corcept Therapeutics is selling for under 57.11 as of the 26th of March 2025; that is 2.07 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 56.52. Corcept Therapeutics has only four percent chance of going through some form of financial distress over the next 2 years but had a somewhat insignificant performance during the last 90 days. The performance scores are derived for the period starting the 26th of December 2024 and ending today, the 26th of March 2025. Click here to learn more.
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California. The company has 105.5 M outstanding shares of which 15.39 M shares are currently shorted by private and institutional investors with about 15.3 trading days to cover. More on Corcept Therapeutics Incorporated
Moving against Corcept Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Corcept Stock Highlights
| President Oncology | Roberto Vieira |
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, ARCA Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Corcept Therapeutics Incorporated (CORT) is traded on NASDAQ Exchange in USA. It is located in 101 Redwood Shores Parkway, Redwood City, CA, United States, 94065 and employs 500 people. Corcept Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.27 B. Corcept Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 105.5 M outstanding shares of which 15.39 M shares are currently shorted by private and institutional investors with about 15.3 trading days to cover.
Corcept Therapeutics Incorporated currently holds about 370.09 M in cash with 198.07 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45.
Check Corcept Therapeutics Probability Of Bankruptcy
Ownership AllocationCorcept Therapeutics holds a total of 105.5 Million outstanding shares. The majority of Corcept Therapeutics Incorporated outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Corcept Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Corcept Therapeutics. Please pay attention to any change in the institutional holdings of Corcept Therapeutics Incorporated as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Corcept Ownership Details
Corcept Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Corcept Therapeutics market risk premium is the additional return an investor will receive from holding Corcept Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0467 | |||
| Jensen Alpha | 0.1596 | |||
| Total Risk Alpha | 0.165 | |||
| Sortino Ratio | 0.049 |
Corcept Stock Against Markets
Corcept Therapeutics Corporate Management
| Hazel Hunt | Chief Officer | Profile | |
| Amy Flood | Chief Officer | Profile | |
| Joseph MD | President, CoFounder | Profile | |
| William PharmD | Chief Officer | Profile | |
| Gary JD | Chief Secretary | Profile |
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.